Skip to content
HealthyStudy
Menu

Type 2 diabetesTwo labels compared

Farxiga vs Jardiance

Farxiga and Jardiance are the two best-known SGLT2 inhibitors, and their labels read closely in parallel: type 2 diabetes, heart failure, chronic kidney disease. The differences live in the wording of the indications, the dosing, and the register: dapagliflozin has FDA-approved generics, empagliflozin does not. This page reads both documents line by line.

Farxiga

Ingredient
Dapagliflozin
Approved for
Type 2 diabetes, heart failure, chronic kidney diseasecovers type 2 diabetes
Supply
Prescription
Boxed warning
None
Pharmacy cost
$12.08 per tablet, capsule or pen, brandwhat pharmacies pay to buy it, not the price at the counter
AstraZeneca Pharmaceuticals LP. Label version 47, effective 3 June 2026.

Jardiance

Ingredient
Empagliflozin
Approved for
Type 2 diabetes, heart failure, chronic kidney diseasecovers type 2 diabetes
Supply
Prescription
Boxed warning
None
Pharmacy cost
$11.20 per tablet, capsule or pen, brandwhat pharmacies pay to buy it, not the price at the counter
Boehringer Ingelheim Pharmaceuticals, Inc.. Label version 31, effective 30 January 2026.
01From the FDA label

Side by side, straight from the labels

Generated from the two source labels, not typed out by hand, so it cannot drift from what the regulator approved. Rows where both labels say exactly the same thing are marked.

Active ingredientFarxigaDapagliflozinSGLT2 inhibitorJardianceEmpagliflozinSGLT2 inhibitor
Approved forsame in bothFarxigaType 2 diabetes, heart failure, chronic kidney diseaseJardianceType 2 diabetes, heart failure, chronic kidney disease
Supplysame in bothFarxigaPrescriptionJardiancePrescription
What pharmacies payAcquisition cost, not retailFarxiga$12.08 per tablet, capsule or pen, brandJardiance$11.20 per tablet, capsule or pen, brand
Boxed warningsame in bothFarxigaNoneJardianceNone
What the FDA approved it forFarxiga
  • To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular (CV) death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression.
  • To reduce the risk of CV death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure.
  • To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established CV disease or multiple CV risk factors.
  • As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.
  • Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus.
  • Not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for the treatment of kidney disease. FARXIGA is not expected to be effective in these populations.
Jardiance
  • JARDIANCE is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. to reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression.
  • JARDIANCE is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated: To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure.
  • To reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.
  • As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.
  • It may increase the risk of diabetic ketoacidosis in these patients.
  • JARDIANCE is not expected to be effective in these populations.
Forms and strengthsFarxiga
  • Tablets: 5 mg and 10 mg
Jardiance
  • JARDIANCE tablets available as: 10 mg pale yellow, round, biconvex and bevel-edged, film-coated tablets debossed with "S 10" on one side and the Boehringer Ingelheim company symbol on the other side. 25 mg pale yellow, oval, biconvex, film-coated tablets debossed with "S 25" on one side and the Boehringer Ingelheim company symbol on the other side.
  • Tablets: 10 mg, 25 mg
How the label says it is takenFarxiga
  • Assess renal function prior to initiation and then as clinically indicated. Assess volume status and correct volume depletion before initiating.
  • To improve glycemic control, the recommended starting dosage is 5 mg orally once daily. Dosage can be increased to 10 mg orally once daily for additional glycemic control.
  • For all other indications, the recommended dosage is 10 mg orally once daily.
  • See full prescribing information for dosage recommendations in patients with renal impairment.
  • Withhold FARXIGA for at least 3 days, if possible, prior to surgery or procedures associated with prolonged fasting. Testing Prior to Initiation of FARXIGA
Jardiance
  • Assess renal function before initiating and as clinically indicated. Assess volume status and correct volume depletion before initiating.
  • Recommended dosage is 10 mg orally once daily in the morning, taken with or without food.
  • For additional glycemic control, dosage may be increased to 25 mg orally once daily in patients tolerating JARDIANCE.
  • Withhold JARDIANCE for at least 3 days, if possible, prior to surgery or procedures associated with prolonged fasting.
Most common adverse reactionsFarxiga
  • Most common adverse reactions (5% or greater incidence) were female genital mycotic infections, nasopharyngitis, and urinary tract infections.
Jardiance
  • Most common adverse reactions (5% or greater incidence) were urinary tract infections and female genital mycotic infections To report SUSPECTED ADVERSE REACTIONS, contact Boehringer Ingelheim Pharmaceuticals, Inc.
Warnings and precautionsFarxiga
  • Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus and Other Ketoacidosis: Consider ketone monitoring in patients with type 1 diabetes mellitus and consider ketone monitoring in others at risk for ketoacidosis, as indicated. Assess for ketoacidosis regardless of presenting blood glucose levels and discontinue FARXIGA if ketoacidosis is suspected.
  • Volume depletion: Before initiating FARXIGA, assess volume status and renal function in the elderly, patients with renal impairment or low systolic blood pressure, and in patients on diuretics. Monitor for signs and symptoms during therapy.
  • Genitourinary Infections, including Urosepsis, Pyelonephritis, Necrotizing Fasciitis of the Perineum (Fournier's Gangrene), and Genital Mycotic Infections: Monitor patients for signs and symptoms of genitourinary infections and treat promptly, if indicated.
  • Hypoglycemia: Consider a lower dose of insulin or the insulin secretagogue to reduce the risk of hypoglycemia when used in combination with FARXIGA. Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus and Other Ketoacidosis In patients with type 1 diabetes mellitus, FARXIGA significantly increases the risk of diabetic ketoacidosis, a life-threatening event, beyond the background rate.
Jardiance
  • Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus and Other Ketoacidosis: Consider ketone monitoring in patients with type 1 diabetes mellitus and consider ketone monitoring in others at risk for ketoacidosis, as indicated. Assess for ketoacidosis regardless of presenting blood glucose levels and discontinue JARDIANCE if ketoacidosis is suspected.
  • Volume Depletion: Before initiating JARDIANCE, assess volume status and renal function in patients with impaired renal function, elderly patients, or patients on loop diuretics. Monitor for signs and symptoms during therapy.
  • Genitourinary Infections, including Urosepsis, Pyelonephritis, Necrotizing Fasciitis of the Perineum (Fournier's Gangrene), and Genital Mycotic Infections: Monitor patients for signs and symptoms of genitourinary infections and treat promptly, if indicated.
  • Hypoglycemia: Adult patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia. In pediatric patients 10 years of age and older, the risk of hypoglycemia was higher regardless of insulin use. Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating JARDIANCE.
  • Lower Limb Amputation: Monitor patients for infections or ulcers of lower limbs, and institute appropriate treatment
  • Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., angioedema) have occurred with JARDIANCE. If hypersensitivity reactions occur, discontinue JARDIANCE, treat promptly, and monitor until signs and symptoms resolve.
ContraindicationsFarxiga
  • History of serious hypersensitivity reaction to dapagliflozin or any of the excipients in FARXIGA.
Jardiance
  • JARDIANCE is contraindicated in patients: with a hypersensitivity to empagliflozin or any of the excipients in JARDIANCE, reactions such as angioedema have occurred.
  • Hypersensitivity to empagliflozin or any of the excipients in JARDIANCE.
Drug interactionsFarxiga
  • • See full prescribing information for information on drug interactions and interference of FARXIGA with laboratory tests.
  • Drug Interactions In Vitro Assessment of Drug Interactions In in vitro studies, dapagliflozin and dapagliflozin 3-O-glucuronide neither inhibited CYP 1A2, 2C9, 2C19, 2D6, or 3A4, nor induced CYP 1A2, 2B6, or 3A4.
  • Dapagliflozin is a weak substrate of the P-glycoprotein (P-gp) active transporter, and dapagliflozin 3-O-glucuronide is a substrate for the OAT3 active transporter.
  • Dapagliflozin or dapagliflozin 3-O-glucuronide did not meaningfully inhibit P-gp, OCT2, OAT1, or OAT3 active transporters.
  • Overall, dapagliflozin is unlikely to affect the pharmacokinetics of concurrently administered medications that are P-gp, OCT2, OAT1, or OAT3 substrates.
  • Effects of Other Drugs on Dapagliflozin Table 5 shows the effect of coadministered drugs on the pharmacokinetics of dapagliflozin in adults.
Jardiance
  • See Table 4 for clinically relevant interactions with JARDIANCE.
  • See full prescribing information for information on drug interactions and interference of JARDIANCE with laboratory tests.
Label versionFarxiga3 June 2026Jardiance30 January 2026
02Written by us

Four indications each, phrased differently

Both labels cover improving glycemic control in type 2 diabetes in adults and pediatric patients aged 10 and older, a heart failure indication, and a chronic kidney disease indication - the last two standing on their own, without requiring diabetes.

The cardiovascular indications differ in shape: Jardiance lists reducing cardiovascular death in adults with type 2 diabetes and established cardiovascular disease; Farxiga lists reducing hospitalization for heart failure in adults with type 2 diabetes who have established cardiovascular disease or multiple risk factors. Close, not identical, and the table above quotes both.

03Written by us

Dosing runs on different numbers

Farxiga starts at 5 mg once daily for glycemic control, increasable to 10 mg, and uses 10 mg for its other indications. Jardiance's recommended dosage is 10 mg once daily in the morning, increasable to 25 mg for additional glycemic control. Both labels tell prescribers to assess renal function and volume status before starting, and both are withheld before surgery involving prolonged fasting.

04Written by us

Same class, same warning profile, no boxed warning

Neither label carries a boxed warning. Both warn about ketoacidosis, volume depletion, genitourinary infections including Fournier's gangrene, and hypoglycemia when combined with insulin or an insulin secretagogue. Both report genital mycotic infections and urinary tract infections among the most common adverse reactions.

05Written by us

The register split: generics on one side only

The FDA register lists 21 approved generic applications for dapagliflozin and none for empagliflozin. That difference does not appear inside either label, but it is the practical difference a reader meets at the pharmacy, and the acquisition costs in the table above reflect it.

06Written by us

What this page does not tell you

It does not say which SGLT2 inhibitor a person should take. The two labels were written from separate trial programs, and choosing between them belongs to a prescriber who knows the person's kidneys, heart and history.

07Written by us

Common questions

Are Farxiga and Jardiance the same drug?
No, but they are the same class. Farxiga is dapagliflozin and Jardiance is empagliflozin, both SGLT2 inhibitors with labels covering type 2 diabetes, heart failure and chronic kidney disease in closely parallel wording.
Which one has a generic?
Dapagliflozin: the FDA register lists 21 approved generic applications for it. Empagliflozin has none; Jardiance is brand-only.
Do they carry boxed warnings?
No. Neither the Farxiga nor the Jardiance label carries a boxed warning; their main warnings are the shared class warnings, quoted on this page.
Do both work without diabetes?
The heart failure and chronic kidney disease indications in both labels stand on their own and do not require type 2 diabetes. The glycemic control indication, by definition, applies to people with type 2 diabetes.
08

Sources

Every fact above comes from one of these documents. The date is the effective date of the label version this page was built from.

Each stripe is one section of the label, each division in a stripe one entry in that section.

09

Other comparisons in this category

Page last updated 29 August 2026

Compiled by the HealthyStudy editorial team from FDA source documents. No medical reviewer is credited on this page, because none reviewed it.